Appeal No. 2003-1418 Page 2
Application No. 09/056,707
with mast cell secretion inhibitory activity, said proteoglycan
comprising a chondroitin sulfate, alone or together with one or more
synergistic adjuvants.
3. The method of claim 1, wherein said adjuvant is a flavonoid.
4. The method of claim 3, wherein said flavonoid is selected from the
group consisting of myrisetin, quercetin, kaempferol, genistin, a 2-
phenylchromone and 2-phenylbenzopyrone.
6. The method of claim 1, wherein said atopic allergic disease is
selected from the group consisting of allergic asthma, allergic
rhinitis, allergic conjunctivitis, allergic otitis media, allergic
dermatitis, food allergy and allergic urticaria.
The examiner relies on the following references:
Wagner et al. (Wagner) 5,260,335 Nov. 9, 1993
Ahmed 5,980,865 Nov. 9, 1999
Claims 1, 3, 4, and 6 stand rejected under 35 U.S.C. § 103 as obvious in
view of Ahmed and Wagner.
We reverse.
Background
“Mast cells are a normal component of connective and mucosal tissues and
play an important role in allergy and inflammation.” Specification, page 1. “Each
mast cell contains up to 500 secretory granules, each storing more than 20 potent
biological compounds. Mast cells secrete the contents of these granules (i.e.,
degranulate) when triggered by various specific and non-specific mechanisms,
such as the allergic reaction involving immunoglobulin E (IgE) and antigen.” Id.
Page: Previous 1 2 3 4 5 6 7 Next
Last modified: November 3, 2007